Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer

被引：64

作者：

Wei, Zhigang ^{[1
]}

Yang, Xia ^{[1
]}

Ye, Xin ^{[1
]}

Huang, Guanghui ^{[1
]}

Li, Wenhong ^{[1
]}

Han, Xiaoying ^{[1
]}

Wang, Jiao ^{[1
]}

Meng, Min ^{[1
]}

Ni, Yang ^{[1
]}

Zou, Zhigeng ^{[1
]}

Wen, Qiang ^{[1
]}

机构：

[1] Shandong First Med Univ, Dept Oncol, Shandong Prov Hosp, 324 Jingwuweiqi Rd, Jinan 250021, Shandong, Peoples R China

来源：

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2019年 / 15卷 / 07期

关键词：

Camrelizumab; lung cancer; microwave ablation; objective response; progression-free survival; PD-1; antibody; CHEMOTHERAPY; COMBINATION; RECURRENCE; NIVOLUMAB; DOCETAXEL; EFFICACY; BLOCKADE; CRITERIA; SAFETY;

D O I：

10.4103/jcrt.JCRT_990_19

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: The present study evaluated the safety and efficacy of camrelizumab (a programmed death-1 antibody) in combination with microwave ablation (MWA) in advanced non-small cell lung cancer (NSCLC). Materials and Methods: A total of 21 patients were prospectively enrolled. MWA was performed in 25 pulmonary lesions during 21 sessions. Camrelizumab was administered 5-7 days after MWA as a dose of 200 mg, which was repeated every 2 weeks until disease progression or intolerable toxicities. The primary endpoints were safety and the objective response rate (ORR). Other endpoints included progression-free survival (PFS) and overall survival (OS). Results: The technical success rate was 100%. No treatment-associated deaths were identified. Major complications, minor complications, and side effects of MWA were observed in 9, 8, and 14 patients, respectively. The main major complications included pneumothorax, pneumonia, hemorrhage, and pleural effusion. The adverse events of camrelizumab included reactive skin capillary hyperplasia (n = 9), hypothyroidism (n = 5), pneumonia (n = 4), fatigue (n = 2), leukopenia (n = 1), and neutropenia (n = 1). Grade 2 and 3 camrelizumab adverse events were identified in eight and three patients, respectively. The ORR was 33.3%, with two patients achieving complete response and five patients achieving partial response. The median PFS was 5.1 months and OS was not reached. Conclusions: Camrelizumab administration combined with MWA was safe in the treatment of advanced NSCLC, and the combination improved the ORR of camrelizumab alone compared to previous reports.

引用

页码：1629 / 1634

页数：6

共 33 条

[1]

Ahmed M, 2014, RADIOLOGY, V273, P241, DOI [10.1148/radiol.14132958, 10.1016/j.jvir.2014.08.027]

[2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[3] Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial [J].

Bauml, Joshua M. ;

Mick, Rosemarie ;

Ciunci, Christine ;

Aggarwal, Charu ;

Davis, Christiana ;

Evans, Tracey ;

Deshpande, Charuhas ;

Miller, Linda ;

Patel, Pooja ;

Alley, Evan ;

Knepley, Christina ;

Mutale, Faith ;

Cohen, Roger B. ;

Langer, Corey J. .

JAMA ONCOLOGY, 2019, 5 (09) :1283-1290

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[8] Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study [J].

Gomez, Daniel R. ;

Blumenschein, George R., Jr. ;

Lee, J. Jack ;

Hernandez, Mike ;

Ye, Rong ;

Camidge, D. Ross ;

Doebele, Robert C. ;

Skoulidis, Ferdinandos ;

Gaspar, Laurie E. ;

Gibbons, Don L. ;

Karam, Jose A. ;

Kavanagh, Brian D. ;

Tang, Chad ;

Komaki, Ritsuko ;

Louie, Alexander V. ;

Palma, David A. ;

Tsao, Anne S. ;

Sepesi, Boris ;

William, William N. ;

Zhang, Jianjun ;

Shi, Qiuling ;

Wang, Xin Shelley ;

Swisher, Stephen G. ;

Heymach, John V. .

LANCET ONCOLOGY, 2016, 17 (12) :1672-1682

[9] Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma [J].

Huang, Jing ;

Xu, Binghe ;

Mo, Hongnan ;

Zhang, Weilong ;

Chen, Xuelian ;

Wu, Dawei ;

Qu, Dong ;

Wang, Xingyuan ;

Lan, Bo ;

Yang, Beibei ;

Wang, Pei ;

Zhang, Hongtu ;

Yang, Qing ;

Jiao, Yuchen .

CLINICAL CANCER RESEARCH, 2018, 24 (06) :1296-1304

[10] Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial [J].

Iyengar, Puneeth ;

Wardak, Zabi ;

Gerber, David E. ;

Tumati, Vasu ;

Ahn, Chul ;

Hughes, Randall S. ;

Dowell, Jonathan E. ;

Cheedella, Naga ;

Nedzi, Lucien ;

Westover, Kenneth D. ;

Pulipparacharuvil, Suprabha ;

Choy, Hak ;

Timmerman, Robert D. .

JAMA ONCOLOGY, 2018, 4 (01)

← 1 2 3 4 →